- Home
- IPSC
as 11-20-2024 4:00pm EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 149.1M | IPO Year: | 2021 |
| Target Price: | $13.00 | AVG Volume (30 days): | 485.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $5.51 | Next Earning Date: | 11-05-2024 |
| Revenue: | $2,684,000 | Revenue Growth: | 7.88% |
| Revenue Growth (this year): | 244.52% | Revenue Growth (next year): | 27.73% |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farid Adrienne | IPSC | Chief Operations Officer | Nov 4 '24 | Sell | $1.23 | 1,033 | $1,267.49 | 135,130 | |
| Carr Douglas | IPSC | SVP Finance & Operations | Nov 1 '24 | Sell | $1.23 | 283 | $347.24 | 317,147 | |
| Quimi Daphne | IPSC | Director | Sep 12 '24 | Buy | $1.53 | 5,000 | $7,657.00 | 5,000 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
Zacks
13 days ago
What Makes Century Therapeutics (IPSC) a New Buy Stock
Simply Wall St.
15 days ago
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
16 days ago
Century Therapeutics Shares Rise After Q3 Beats Estimates
Zacks
16 days ago
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
16 days ago
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
16 days ago
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire
17 days ago
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Simply Wall St.
24 days ago
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.